Proof of Pharmacology, Safety, and Pharmacokinetics of the Novel TRPA1 Antagonist BI 1839100: A Randomized, Placebo‐Controlled, Parallel Group, First‐In‐Human Study in Healthy Male Participants

Ähnliche Einträge

• Breaking Barriers: Characterization of the Intradermal Lipopolysaccharide Challenge as an In Vivo Model for Controlled Induction of Vascular Leakage in Healthy Volunteers
  von: Marella Cornelia Elizabeth van Ruissen, et al.
  Veröffentlicht: (2025)
• Adverse immunostimulation in early phase clinical trials: Key findings and recommendations based on the investigator's clinical experience
  von: Juliette A. van den Noort, et al.
  Veröffentlicht: (2025)
• Effects of the phosphodiesterase 2 inhibitor BI 474121 on central nervous system cyclic guanosine monophosphate concentrations: Translational studies
  von: Sebastiaan van Kraaij, et al.
  Veröffentlicht: (2024)
• Effect of Once‐Daily Macitentan 75 mg on the Pharmacokinetics of Sildenafil, Riociguat, or Rosuvastatin in Healthy Male Participants
  von: Dénes Csonka, et al.
  Veröffentlicht: (2026)
• Safety, Tolerability, and Pharmacokinetics of Donanemab in Healthy Chinese Participants: A Phase 1, Randomized, Double‐Blind, Placebo‐Controlled Study
  von: Junyu Xu, et al.
  Veröffentlicht: (2025)